Remove Clinical Research Remove Cosmetics Remove FDA Compliance Remove Trials
article thumbnail

FDA End-of-Year Release of Warning Letters Impresses (or Depresses)

FDA Law Blog

Perhaps FDA wanted us to remember 2023 as the year FDA succeeded in uncovering critical defects in drug and device manufacturing, and in critical trials. If FDA wanted to create that impression, it likely succeeded. Patcos Cosmetics Pvt. Finally, FDA said in a Warning Letter that a Clinical Investigator, Anish S.